Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

B. Riley Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $25

Author: Benzinga Newsdesk | March 21, 2024 10:05am

B. Riley Securities analyst Kalpit Patel maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $29 to $25.

Posted In: VRDN